Brind.

A person, Paulo Fontoura, whose background includes work at Hoffmann-La Roche, contributed to successful FDA approvals.

1 report, 1 independent Updated Jun 22

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

FDA Paulo Fontoura Hoffmann-La Roche

Keep exploring

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
Paulo Fontoura
researcher (ORCID 0000-0002-3883-257X)

Nothing else this week.
Hoffmann-La Roche
Swiss healthcare company
- Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation.Sun 02:44
- Hoffmann-La Roche opened a new R&D center in Boston.Sat 11:08

Coverage

Newest first; wire copies grouped

Jun 22webwire.com